News
A federal judge rejected Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic ...
A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart failure ...
Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...
A federal judge has denied Novartis (SIX:NOVN)’ request for a preliminary injunction that would have prevented MSN Pharmaceuticals from selling a generic version of heart medication Entresto.
A Delaware federal judge has ruled that Novartis cannot prevent MSN Pharmaceuticals from introducing a generic version of its ...
Washington: In a significant legal setback for Novartis, a Delaware federal judge has said that Swiss pharmaceutical giant ...
Explore more
The company's quarterly core operating profit--the company's preferred earnings metric, which strips out exceptional and other one-off items--is forecast at $5.75 billion, according to the same ...
2d
Trade Brains on MSNPharma stock falls 4% after competitor acquires U.S. patent for heart failure medicineThe shares of one of India's leading API manufacturers, engaged in the production and export of APIs, intermediates, and ...
A U.S. judge ruled against Novartis, allowing MSN Pharmaceuticals to launch a generic version of Entresto prior to its patent expiry next year. Novartis plans to appeal the decision, which could ...
Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results